Approach to optic neuritis: An update

• Type of Material: Article
• Authors: Swati Phuljhele, All India Institute of Medical Sciences; Sachin Kedar, Emory University; Rohit Saxena, All India Institute of Medical Sciences
• Language: English
• Date: 2021-09-01
• Publisher: Medknow Publications
• Publication Version: Final Published Version
• Copyright Statement: © 2021 Indian Journal of Ophthalmology
• License: Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.4103/ijo.IJO_3415_20
• Title of Journal or Parent Work: INDIAN JOURNAL OF OPHTHALMOLOGY
• Volume: 69
• Issue: 9
• Start Page: 2266
• End Page: 2276
• Grant/Funding Information: Nil.
• Keywords: neuromyelitis optica; Myelin oligodendrocytes; multiple sclerosis; optic neuritis
• Research Categories: Biology, Anatomy; Biology, Neuroscience; Physics, Optics

Abstract

Over the past few years, there has been remarkable development in the area of optic neuritis. The discovery of new antibodies has improved our understanding of the pathology of the disease. Antiaquaporin4 antibodies and antimyelin oligodendrocytes antibodies are now considered as distinct entities of optic neuritis with their specific clinical presentation, neuroimaging characteristics, treatment options, and course of the disease. Similarly, there has been a substantial change in the treatment of optic neuritis which was earlier limited to steroids and interferons. The development of new immunosuppressant drugs and monoclonal antibodies has reduced the relapses and improved the prognosis of optic neuritis as well as an associated systemic disease. This review article tends to provide an update on the approach and management of optic neuritis.